The 1st regulatory approval of a stem-cell drug in the world as Stem cell treatment gets limited approval in Canada Read more…
Net loss was $1.3M or $0.04 Read more…
Net income was $5M or $0.15 per share Read more…
Osiris has notified Sanofi that it is treating Sanofi’s quarterly statement as an intention to terminate Read more…
OSIR down as much as 6.95% after Sanofi announced discontinuation of development of Prochymal in Graft-vs.-Host Disease (GvHD. Read more…
Net income was $4M or $0.12 per diluted share Read more…
Net income of $1.79M or $0.05 per share Read more…
Net income was $1.79M and earnings per share were $0.05 Read more…
OSIR’s alliance is at risk on Genzyme takeover, however … Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.